Highlight Therapeutics Overview
- Founded
-
2010

- Status
-
Private
- Employees
-
23

- Latest Deal Type
-
2ndary - Private
- Investors
-
8
Highlight Therapeutics General Information
Description
Developer of RNA-based immuno-oncology therapies designed to combat cancer in patients. The company's therapies recapitulate the effect of viral infection and enhance the therapeutic effect of drugs, enabling medical professionals to promote the speedy recovery of tumors in patients.
Contact Information
Website
www.highlighttherapeutics.com
Formerly Known As
Bioncotech
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Parque Científico Universidad de Valencia
- Calle Catedrático Agustín Escardino, 9, Paterna
- 46980 Valencia
- Spain
+34 961 00 00 00
Highlight Therapeutics Timeline
Highlight Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
9. Secondary Transaction - Private | 15-Jul-2022 | 000.00 | Completed | Clinical Trials - Phase 2 | ||
8. Later Stage VC | 00.000 | 000.00 | Completed | Clinical Trials - Phase 2 | ||
7. Later Stage VC | 05-Feb-2021 | 000.00 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 2 |
6. Later Stage VC | 20-Nov-2019 | 00.000 | 000.00 | 000.00 | Completed | Generating Revenue |
5. Later Stage VC | 03-Feb-2017 | 00.000 | 000.00 | 00.00 | Completed | Clinical Trials - Phase 2 |
4. Later Stage VC | 06-Oct-2016 | 00.000 | 000.00 | 000.00 | Completed | Pre-Clinical Trials |
3. Grant | 01-Jan-2016 | 00000 | 000.00 | Completed | Pre-Clinical Trials | |
2. Early Stage VC (Series A) | 01-Jan-2013 | $14.4M | $14.4M | 000.00 | Completed | Pre-Clinical Trials |
1. Accelerator/Incubator | 01-Jan-2010 | Completed | Pre-Clinical Trials |
Highlight Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
Ordinary | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
Ordinary | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
Ordinary | 54,720 | $1.213472 | $67.69 | $67.69 | 1x | $67.69 | 1.25% | |
Ordinary | 198,840 | $1.213472 | $67.13 | $67.13 | 1x | $67.13 | 4.53% |
Highlight Therapeutics Executive Team (5)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Marisol Quintero Ph.D | Chief Executive Officer | ||
Gema Alonso | Global Chief Financial Officer & HR and Vice President of Finance | ||
Mercedes Pozuelo Rubio Ph.D | Director of CMC | ||
Damià Tormo Ph.D | Co-Founder & Board Member |
Highlight Therapeutics Board Members (6)
Name | Representing | Role | Since |
---|---|---|---|
Bart Hooland | Droia Oncology Ventures | Board Member | 000 0000 |
Carlos Paya Ph.D | Highlight Therapeutics | Chairman | 000 0000 |
Damià Tormo Ph.D | Self | Co-Founder & Board Member | 000 0000 |
Luc Dochez | Droia Oncology Ventures | Board Member | 000 0000 |
Highlight Therapeutics Signals
Highlight Therapeutics Investors (8)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Columbus Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Advent Life Sciences | Venture Capital | Minority | 000 0000 | 000000 0 | |
Centro para el Desarrollo Tecnológico Industrial | Government | 000 0000 | 000000 0 | ||
European Regional Development Fund (Brandenburg) | Sovereign Wealth Fund | 000 0000 | 000000 0 | ||
Ministerio de Economía, Industria y Competitividad | Government | 000 0000 | 000000 0 |